Turn on more accessible mode
Turn off more accessible mode
Home
|
Media Center
|
Careers
Personal
Accounts
Loans
eBanking
NRI Business
Other Services
Corporate
Corporate Banking
International Banking
Syndicated Loans
Trade Finance
Long Term Finance
Working Capital Facilities
SMEs Facility Application – Law (2) – 2021
Investor Relations
Our Strategy
Financials
Financial News
BBK News
Local & Global Market
Shareholder's Queries
Customer Service
Branch Timing
Request for Support
Security Center
FAQ
Tutorials
Contact Us
About Us
About Us
BBK Network
Subsidiaries
Board of Directors
Executive Management
Divisions
Corporate Governance
Awards
BBK awarded for distinguished Corporate Governance practices
Bahrain’s pioneer in commercial and retail banking
BBK wins first place for excellence in Corporate Governance practices
BBK wins Bahrain eContent Award
BBK newsletter
CINET
BBK Press releases
Latest News
Archives
Financial News
Latest News
Archives
Internet Banking
Retail login
Help
|
Alert
What do you want to do?
Select here
Access Retail Internet Banking
Home
Media Center
Financial News
Archives
Archives
01-07-14
Tabuk Pharmaceuticals to sign commercial deal with Pfizer
(MENAFN) Tabuk Pharmaceuticals, one of the leading pharmaceutical companies in the Middle East and North Africa region (MENA), has signed a commercial agreement with Pfizer, the US-based global industry leader, Saudi Gazette reported. The venture leverages the respective companies' market leading presence in the Kingdom of Saudi Arabia, to deliver increased value to patients in the Cardiovascular, Central Nervous System, Anti-infective and Respiratory therapeutic areas. Under the agreement, Pfizer will grant Tabuk exclusive rights to carry out manufacturing processes under license commercialize and distribute second brand versions of four Pfizer products in the Kingdom of Saudi Arabia. In addition, Tabuk Pharmaceuticals will give Pfizer, rights to twelve high-value generic products in Saudi Arabia. Both companies will seek the relevant authorities' approvals for registration, production and commercialization. The project is aligned with one of Tabuk Pharmaceuticals' main strategic objective: to expand its offering of innovative medicines in Saudi Arabia, by strengthening its position in its domestic market through partnerships with multinational companies. In so doing, Tabuk Pharmaceuticals continues to deliver on its mission to help improve the lives of patients, while contributing to the development of KSA's local pharmaceutical industry and manufacturing expertise.
View complete sitemap
Personal
Accounts
Loans
Mortgage
eBanking
ATM
Internet Banking
SMS Banking
NRI Business
Other Services
Corporate
Corporate Banking
International Banking
Syndicated Loans
Trade Finance
Long Term Finance
Working Capital Facilities
SMEs Facility Application – Law (2) – 2021
Investor Relations
Our Strategy
Financials
LCR Reports
Financial News
BBK News
Local & Global Market
Shareholder's Queries
Customer Service
Branch Timing
Request for Support
Security Center
FAQ
BBK tariffs
Tutorials
Customer Protection
Contact Us
About Us
About Us
BBK Network
Subsidiaries
Board of Directors
Executive Management
Divisions
Corporate Governance
Follow us